Stocks · News reference
MiNK Therapeutics Says First Patients Treated With agenT-797 In Phase 2 Severe Hypoxemic Pneumonia Trial Alive At Day 28 With Improved Oxygenation, Infection Control
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript
MiNK Therapeutics (NASDAQ:INKT) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to
8-K filing — MiNK Therapeutics, Inc. (INKT)
Filed: 2026-08-13 AccNo: 0001193125-26-347907 Size: 215 KB Item 2.02: Results of Operations and Financial Condition
MiNK Therapeutics Announces Launch Of Paid International Named-Patient Access Program For agenT-797 In Brazil With Orphan Drug Consulting